AKRO AKERO THERAPEUTICS INC

Ownership history in Aberdeen Group plc  ·  8 quarters on record

This page tracks every 13F SEC filing in which Aberdeen Group plc reported a position in AKERO THERAPEUTICS INC (AKRO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.04% (2025 Q3)
Avg. % of fund
0.02%
First filed
2023 Q4
Last filed
2025 Q3
Quarters held
8
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 502,913 +111,313 +28.4% 0.04% $23.9M
2025 Q2 REDUCED 391,600 -15,100 -3.7% 0.04% $20.9M
2025 Q1 ADDED 406,700 +136,918 +50.8% 0.03% $16.5M
2024 Q4 ADDED 269,782 +146,424 +118.7% 0.01% $7.5M
4 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)

Other funds also holding AKRO

As of 2025 Q4 — sorted by position size

Nebula Research & Development LLC 0.07% IFP Advisors, Inc 3Y 7Y 0.0%
← Back to Aberdeen Group plc Holdings